FDA accepts lixisenatide NDA for review
Posted: 29 September 2015 |
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study…
The US Food and Drug Administration (FDA) has accepted Sanofi‘s New Drug Application (NDA) for lixisenatide, an investigational once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus (T2DM), for filing.
“The FDA filing notification for lixisenatide is an important milestone for Sanofi,” said Pierre Chancel, Senior Vice President, Head of Global Diabetes at Sanofi. “Sanofi’s integrated portfolio of marketed products provides treatment, monitoring and support at every stage of the diabetes journey. Lixisenatide is a critical element of this portfolio, and we look forward to working with the FDA during the review process with the goal of bringing lixisenatide to patients in the US.”
Lixisenatide NDA base on results from the GetGoal clinical programme
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study, the first completed long-term CV outcomes study of a GLP-1 receptor agonist. The GetGoal Phase III clinical programme enrolled more than 5,000 patients worldwide, evaluating the safety and efficacy of lixisenatide, including its treatment effect on HbA1c, post-prandial glucose and body weight in adults with T2DM. The ELIXA trial evaluated the cardiovascular safety of lixisenatide versus standard of care in more than 6,000 adults with T2DM and high CV risk (i.e., patients who have recently experienced a spontaneous acute coronary syndrome event).
The proprietary name for lixisenatide in the United States is under consideration. Lyxumia is the proprietary name approved by the European Medicines Agency and other health authorities.